08:02 EST Protara Therapeutics (TARA) down 18% at $5.66 after equity offering
Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on TARA:
- Protara Therapeutics 13.04M share Spot Secondary priced at $5.75
- Protara Therapeutics $75M Spot Secondary; price range $5.75-$6.25
- Protara Therapeutics announces $75M common stock offering
- Protara’s TARA-002: Promising Efficacy and Clear Regulatory Path Justify Buy Rating
- Buy Rating for Protara Therapeutics Driven by Promising Bladder Cancer Drug Trial